Tomudex
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inoperable or Recurrent Rectal Cancer
Conditions
Inoperable or Recurrent Rectal Cancer
Trial Timeline
Aug 1, 2002 → —
NCT ID
NCT00590278About Tomudex
Tomudex is a phase 2 stage product being developed by AstraZeneca for Inoperable or Recurrent Rectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00590278. Target conditions include Inoperable or Recurrent Rectal Cancer.
What happened to similar drugs?
0 of 2 similar drugs in Inoperable or Recurrent Rectal Cancer were approved
Approved (0) Terminated (0) Active (2)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00590278 | Phase 2 | Completed |
Competing Products
10 competing products in Inoperable or Recurrent Rectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin Mesylate | Eisai | Pre-clinical | 26 |
| Premetrexed (Alimta) + Carboplatin | Eli Lilly | Phase 1 | 29 |
| Fulvestrant + Capivasertib + Placebo | AstraZeneca | Phase 3 | 44 |
| Selumetinib | AstraZeneca | Pre-clinical | 26 |
| Cisplatin + Gemcitabine + Selumetinib | AstraZeneca | Phase 1 | 21 |
| Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | AstraZeneca | Phase 3 | 47 |
| Drug (including placebo) | Merck | Phase 1 | 21 |
| BEZ235 + Paclitaxel | Novartis | Phase 1/2 | 24 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 39 |
| dacomitinib hydrate | Pfizer | Pre-clinical | 26 |